PGR
EstablishedPGR/progesterone receptor status, paired with ER, guides breast cancer hormone therapy eligibility.
The progesterone receptor is tested alongside the estrogen receptor in breast cancer to help decide whether hormone-blocking treatment will work well. A tumor with one receptor but not the other is a less common, less well-understood pattern.
PGR encodes the progesterone receptor, tested alongside the estrogen receptor (ESR1) in breast cancer to determine eligibility for hormone (endocrine) therapy.
Progesterone receptor positivity, combined with estrogen receptor status, guides the decision to use hormone therapy in breast cancer; PR-positive/ER-negative tumors are rare and their optimal treatment approach is less well-established than the more common ER-positive/PR-positive pattern.
Measured via immunohistochemistry on tumor tissue, reported as a percentage of positive-staining cells alongside ER and HER2 status, forming the standard breast cancer biomarker panel used to classify tumor subtype and guide treatment.
ER-positive/PR-positive tumors generally respond best to hormone therapy; PR-negative status within an ER-positive tumor is associated with somewhat reduced hormone therapy responsiveness and is factored into overall treatment planning alongside other markers.
The uncommon PR-positive/ER-negative combination has a less well-established optimal treatment approach.
- General breast oncology reference literature on ER/PR/HER2 testing and hormone receptor-positive breast cancer treatment selection.